10-K: Neuphoria Advances BNC210, Secures Merck Milestone

Neuphoria Therapeutics Inc. reports progress in its clinical pipeline for neuropsychiatric disorders, including BNC210 in Phase 3 for SAD and Phase 2b/3 for PTSD, alongside a $15 million milestone payment from Merck.

Summary

• Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on neuropsychiatric disorders, with its lead candidate BNC210 in advanced clinical trials.
• BNC210 is an oral, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, being developed for acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD).
• The company received a $15 million milestone payment from Merck & Co., Inc. in March 2025, triggered by the initiation of a Phase 2 clinical trial for MK-1167 (an α7 receptor PAM) for Alzheimer's disease dementia.
• Neuphoria is eligible for up to $450 million in additional research and commercial milestone payments from Merck, plus royalties on net sales.
• Patient screening for the Phase 3 AFFIRM-1 trial of BNC210 for acute SAD began in July 2024, targeting 332 adult patients in the U.S., with topline results expected early in Q4 calendar 2025.
• The Phase 2b ATTUNE trial for BNC210 in PTSD met its primary endpoint, showing statistically significant improvement in CAPS-5 total symptom severity score at Week 12 (p=0.048), and also improved depressive symptoms (p=0.041) and sleep (p=0.039).
• An End-of-Phase 2 meeting with the FDA in July 2024 provided a potential path to NDA submission for BNC210 in PTSD, requiring a single additional registrational trial.
• Neuphoria also received a A$1 million milestone payment from Carina Biotech in October 2024 for the initiation of a Phase 1 clinical trial of CNA3103 (LGR5 CAR-T technology) for solid tumors.
• The company reported a net loss of $0.4 million for the fiscal year ended June 30, 2025, a significant improvement from a $15.5 million net loss in the prior year, primarily due to the Merck milestone payment.
• Cash and cash equivalents stood at $14.2 million as of June 30, 2025, with an accumulated deficit of $178.3 million.
• Management believes existing cash and cash equivalents, combined with anticipated financing, will fund development activities through Q2 fiscal year 2027.
• The company's redomiciliation from Australia to Delaware was completed on December 23, 2024, with shares now trading on Nasdaq under 'NEUP'.

Sentiment

Score: 7

Explanation: The company demonstrated significant progress in its clinical pipeline with positive Phase 2b PTSD results and advancement to Phase 3 for SAD. The substantial milestone payment from Merck significantly improved the financial position and extended the cash runway. While capital raises are still needed for future trials and there were some clinical setbacks (PREVAIL primary endpoint miss, LFT findings in ATTUNE), the overall trajectory, regulatory agreements, and financial inflows indicate a positive outlook for a clinical-stage biotech.

Positives

• Received a $15 million milestone payment from Merck in March 2025 for the initiation of a Phase 2 clinical trial for MK-1167 in Alzheimer's disease dementia.
• Eligible for up to $450 million in additional milestone payments and royalties from the Merck collaboration.
• Phase 2b ATTUNE trial for BNC210 in PTSD met its primary endpoint (CAPS-5 total symptom severity score, p=0.048) and showed significant improvements in depressive symptoms (p=0.041) and sleep (p=0.039).
• Positive outcome from End-of-Phase 2 FDA meeting for BNC210 in PTSD, outlining a potential path to NDA submission with a single additional registrational trial.
• Initiated patient screening for the Phase 3 AFFIRM-1 trial of BNC210 for acute SAD in July 2024, with topline results expected early Q4 calendar 2025.
• BNC210 has Fast Track designation from the FDA for both PTSD and SAD programs.
• Received a A$1 million milestone payment from Carina Biotech in October 2024 for the initiation of a Phase 1 clinical trial for CNA3103.
• Net loss significantly decreased to $0.4 million in FY2025 from $15.5 million in FY2024, largely due to milestone revenue.
• Management believes existing cash and anticipated financing will fund operations through Q2 fiscal year 2027, indicating no substantial doubt about going concern for the next 12 months.
• The new tablet formulation of BNC210 overcomes the food effect, improves patient compliance, and provides rapid absorption, making it suitable for acute treatment.

Negatives

• The Phase 2 PREVAIL trial for BNC210 for acute SAD narrowly missed its primary endpoint, requiring post-hoc analysis to identify encouraging trends.
• The company has incurred significant operating losses since inception, with an accumulated deficit of $178.3 million as of June 30, 2025.
• Future clinical trials for BNC210 in SAD (AFFIRM-2) and PTSD (SYMPHONY) are contingent upon having sufficient capital on hand.
• Observed 14 reports of elevated liver function tests (LFT) results in participants receiving BNC210 900 mg twice daily in the ATTUNE PTSD study, requiring a lower dose to be tested in future trials and a hepatic safety monitoring plan.
• The FDA denied the initial request for Breakthrough Therapy designation for BNC210 in February 2025.
• The company is highly dependent on senior management and scientific staff, and difficulties in attracting and retaining key personnel could harm the business.
• Reliance on third parties for manufacturing and clinical trials introduces risks of non-compliance, delays, or supply disruptions.
• Limited information rights under the Merck collaboration mean dependence on Merck for updates, which may be withheld at their sole discretion.
• The company's ability to utilize tax losses and certain other tax attributes may be limited due to potential ownership changes under Australian tax law.
• The company is not currently paying dividends and does not anticipate doing so in the foreseeable future.

Risks

• Lack of operating history and need for additional capital: The company has incurred significant operating losses and will require substantial additional financing to achieve its goals, with no guarantee of profitability.
• Clinical trial failures: Product candidates may fail to demonstrate safety and efficacy in clinical trials, leading to delays, increased costs, or termination of development programs.
• Regulatory approval delays or denials: Inability to obtain or delays in obtaining required regulatory approvals from the FDA or comparable foreign authorities would prevent commercialization.
• Adverse side effects: Product candidates may cause undesirable side effects, leading to trial suspensions, restrictive labels, or withdrawal of marketing approval.
• Smaller market opportunities: The estimated patient populations for SAD, PTSD, or other indications may be smaller than anticipated, or approvals may be for narrower populations, limiting revenue.
• Ongoing regulatory obligations: Even if approved, products are subject to extensive ongoing regulatory requirements, with potential penalties for non-compliance.
• Failure to obtain Breakthrough Therapy or Fast Track designation: While Fast Track was granted for BNC210, denial of Breakthrough Therapy designation means no expedited development or review process.
• Reliance on third parties: Extensive reliance on CROs, CMOs, and collaboration partners for development, manufacturing, and commercialization introduces risks of non-performance, non-compliance, or termination of agreements.
• Competition: The biopharmaceutical industry is highly competitive, with larger companies having greater resources, potentially leading to competitors developing and commercializing drugs more successfully or rapidly.
• Third-party payor coverage and reimbursement uncertainty: Failure to obtain or maintain adequate coverage and reimbursement for approved products could limit market access and revenue generation.
• Product liability claims: Inherent risks in testing, manufacturing, and marketing human therapeutic drugs expose the company to potential liability claims, which may not be adequately covered by insurance.
• Changes in healthcare laws and regulations: Legislative reforms, such as the Inflation Reduction Act and the One Big Beautiful Bill Act, could adversely affect business and results of operations, including drug pricing and reimbursement.
• Data privacy and security breaches: Failures in internal computer systems or those of third parties could disrupt development programs, lead to data loss, or incur liability and reputational damage.
• Intellectual property protection: Inability to obtain and maintain sufficient patent and other IP protection, or challenges to existing patents, could allow competitors to commercialize similar products.
• Dependence on key personnel: High reliance on senior management and scientific staff, with difficulties in attracting and retaining qualified personnel, could harm the business.
• Market price volatility: The trading price of common stock has been highly volatile and could fluctuate significantly due to various factors, including clinical trial results, regulatory actions, and economic conditions.
• Delisting risk: Failure to meet Nasdaq's continued listing requirements could result in delisting, negatively impacting share price and capital raising ability.
• Inflation: Increases in inflation could raise costs for commodities, labor, materials, and services, adversely impacting financial condition.

Future Outlook

The company anticipates continued net losses for the foreseeable future as it advances BNC210 through clinical development and seeks regulatory approvals. Expenses are expected to increase with ongoing clinical trials, expanded R&D efforts, and costs associated with being a U.S. public company. Future financing will be required beyond Q2 fiscal year 2027. The company plans to initiate the AFFIRM-2 trial in SAD and the SYMPHONY trial in PTSD in the first half of 2026, contingent on successful outcomes of AFFIRM-1 and sufficient capital. It also aims to expand BNC210's indication potential and build a U.S. commercialization infrastructure, while maximizing preclinical and legacy oncology assets through partnerships.

Management Comments

• "Our goal is to be a leading biopharmaceutical company focused on the development and commercialization of novel treatments to transform the lives of patients with serious CNS disorders with high unmet medical need."
• "We believe BNC210 has broad potential across acute and chronic anxiety and stressor-related disorders with high unmet medical need."
• "Management believes that the application of discounted cash flows of observable market comparables for one drug compound is reasonable to be applied to other compounds within the reporting unit at their respective development phases."
• "Management believes that any reasonably possible change in the key assumptions on which recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate fair value of the reporting unit."
• "Management has determined there is no substantial doubt regarding the Company's ability to continue as a going concern for the twelve month period from the date these financial statements are issued."
• "Our IT Manager is actively involved in assessing, monitoring and managing our cybersecurity risks. He has over 30 years of experience in the field of cybersecurity, and his in-depth knowledge and experience are instrumental in developing and executing our cybersecurity strategies."

Industry Context

The biopharmaceutical industry is highly competitive, characterized by rapid technological change and significant unmet medical needs in neuropsychiatric disorders like SAD and PTSD, where no new FDA-approved therapies have emerged in nearly two decades. Existing treatments (antidepressants, benzodiazepines) have limitations such as slow onset, significant side effects, and abuse potential. Neuphoria's focus on α7 receptor modulation with BNC210 represents an attempt to address these shortcomings with a novel mechanism of action, aiming for rapid relief without common pitfalls. The industry also sees significant M&A activity and reliance on collaborations (like Neuphoria's with Merck and Carina) to fund capital-intensive R&D. Recent legislative changes like the Inflation Reduction Act and the One Big Beautiful Bill Act are impacting drug pricing, R&D tax incentives, and orphan drug profitability, creating a dynamic regulatory and economic environment for biotech companies.

Comparison to Industry Standards

• BNC210's observed fast onset of action and clinical activity without sedation, cognitive impairment, or addiction in clinical trials contrasts favorably with current pharmacological treatments for SAD and PTSD, such as SSRIs/SNRIs (slow onset, significant side effects including suicidality risk) and benzodiazepines (sedation, memory/motor impairment, abuse liability, addiction potential).
• In a head-to-head study, BNC210 300 mg statistically significantly reduced the intensity of defensive behavior compared to placebo, while lorazepam (a widely prescribed benzodiazepine) did not, suggesting a potentially superior profile in certain anxiety responses.
• The therapeutic effects of BNC210 in the PREVAIL study's post-hoc analysis were found to be comparable to those reported with benzodiazepines, but without the associated side effects, indicating a competitive efficacy profile with an improved safety profile.
• The company's strategy to target ion channels for CNS disorders is a recognized, yet complex, area of drug development, with many companies having struggled to bring such modulators to market due to drug discovery limitations and off-target activity of conventional agonists.
• The receipt of a $15 million milestone payment from Merck for advancing MK-1167 into Phase 2 for Alzheimer's disease dementia, and eligibility for up to $450 million in additional milestones, aligns with industry standards for successful early-stage collaboration and validation of platform technology.

Management Changes

Corporate Governance

Legal Proceedings

• Management is not aware of any current formal claims or actions pending against the company that could have a material adverse effect on results of operations, financial condition, or cash flows.

Related Party Transactions

• Consulting agreement with Danforth Advisors LLC (amended May 2023, August 2023) for CFO services provided by Tim Cunningham. Payments to Danforth were $378,631 in FY2025 and $734,648 in FY2024.
• Engagement letter with WG Partners LLP (December 2023) for financial advisory services. David Wilson, a director, is Chairman and CEO of WG Partners. Payments to WG Partners were $148,971 in FY2025 and $189,112 in FY2024.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises, but also potential for increased value from successful clinical development and commercialization of product candidates. The redomiciliation to the U.S. and Nasdaq listing aims to enhance investor access and liquidity.
• Employees: Continued investment in R&D and potential commercialization infrastructure could lead to job growth. Equity incentive plans are designed to attract, retain, and motivate employees.
• Patients: Development of BNC210 aims to address significant unmet medical needs in SAD and PTSD, potentially offering a well-tolerated, fast-acting therapeutic alternative to existing treatments with limiting side effects.
• Collaboration Partners (Merck, Carina Biotech): Continued partnership success could lead to further milestone payments and royalties for Neuphoria, while partners benefit from licensed technologies and potential product commercialization.
• Creditors: The company's ability to continue as a going concern through Q2 FY2027, supported by milestone payments and anticipated financing, provides some stability, but future capital raises remain crucial.

Next Steps

• Topline results from the Phase 3 AFFIRM-1 trial for BNC210 in SAD are expected early in the fourth quarter of calendar 2025.
• Plan to initiate the AFFIRM-2 trial in SAD in the first half of 2026, contingent upon successful outcomes of AFFIRM-1 and sufficient capital.
• Plan to initiate the Phase 2b/3 SYMPHONY trial in PTSD in the first half of 2026, contingent upon having sufficient capital on hand.
• Finalize the full study protocol for the Phase 2b/3 trial in PTSD, including testing a lower dose of BNC210 and implementing a hepatic safety monitoring plan.
• Continue to evaluate BNC210's potential for acute and chronic treatment of additional anxiety indications such as GAD, panic disorder, and chronic SAD.
• Build a commercialization infrastructure in the United States for BNC210, if approved.
• Evaluate strategic opportunities for BNC210 outside the United States with collaborators.
• Advance early-stage CNS programs (α7 nicotinic acetylcholine receptor next generation and Kv3.1/3.2 preclinical programs) either internally or through new partnerships.
• Continue to advance legacy oncology programs (BNC101, BNC105) through existing and future external funding and out-licensing.
• Strategically expand the clinical pipeline through acquisitions, licenses, and/or collaborations.
• Hold the 2025 annual general shareholder meeting on or about November or December 2025 to regain Nasdaq compliance.

Key Dates

Recommendation

Neuphoria Therapeutics Inc. shows promising clinical progress with BNC210 in both SAD and PTSD, backed by positive Phase 2b results and clear regulatory pathways for registrational trials. The significant milestone payment from Merck has substantially improved the company's financial runway, alleviating immediate liquidity concerns. However, the company remains a clinical-stage entity with an accumulated deficit, and future trials are contingent on securing additional capital. The prior miss of a primary endpoint in the PREVAIL study and LFT findings in ATTUNE highlight inherent risks in drug development. While the long-term potential is considerable given the unmet medical needs in its target indications, the stock carries substantial risk due to its early stage of commercialization and ongoing financing requirements. A 'hold' recommendation is appropriate, acknowledging the positive developments and extended cash runway, but also the significant execution risks and capital needs ahead. Investors should monitor upcoming clinical trial results and financing activities closely.

Keywords

Neuphoria Therapeutics, BNC210, Social Anxiety Disorder, SAD, Post-Traumatic Stress Disorder, PTSD, Neuropsychiatric Disorders, Clinical Trials, Phase 3, Phase 2b/3, Merck, Milestone Payment, Biotechnology, Drug Development, SEC Filing, 10-K, α7 nicotinic acetylcholine receptor, NAM, PAM, Alzheimer's Disease, Carina Biotech, Oncology, LGR5 CAR-T, Financial Results, Nasdaq, FDA, Fast Track Designation